As of November 6, 2026, 8 holders' latest Schedule 13D or 13G filings report owning 5% or more of Femasys Inc. The largest reported stake is Alumni Capital LP's, at 9.99%. 8 filings are on record since August 5, 2025 (Schedule 13G, September 4, 2025).
Sell to companies like Femasys Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Empery Asset Management, LP · Sole voting: 0 · Shared voting: 468,750 · Sole dispositive: 0 · Shared dispositive: 468,750 · SCHEDULE 13G, 2026-10-15
- · Reporting person: Stonepine Capital Management, LLC · Sole voting: 0 · Shared voting: 625,000 · Sole dispositive: 0 · Shared dispositive: 625,000 · SCHEDULE 13G, 2026-08-31
- · Reporting person: Nantahala Capital Partners Limited Partnership · Sole voting: 0 · Shared voting: 803,038 · Sole dispositive: 0 · Shared dispositive: 803,038 · SCHEDULE 13D, 2026-08-17
- · Reporting person: Rosalind Advisors, Inc. · Sole voting: 0 · Shared voting: 4,687,500 · Sole dispositive: 0 · Shared dispositive: 4,687,500 · SCHEDULE 13G, 2026-08-14
- · Holder: PharmaCyte Biotech, Inc. · Percent: 7.87% · SCHEDULE 13G
Femasys Inc. has 8 Schedule 13D or 13G filings on record since 2025-08-05. 8 holders' latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Alumni Capital LP | 9.99% | 4,773,579 | SCHEDULE 13G, 2025-09-04 | 2025-09-04 |
| Nantahala Capital Partners Limited Partnership | 9.99% | 803,038 | SCHEDULE 13D, 2026-08-17 | 2026-08-10 |
| Dauntless Investment Group, LLC | 9.9% | 4,395,996 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Rosalind Advisors, Inc. | 9.9% | 4,687,500 | SCHEDULE 13G, 2026-08-14 | 2026-08-10 |
| 9.3% | 3,034,335 | SCHEDULE 13G/A, 2025-08-05 | 2025-06-30 | |
| PharmaCyte Biotech, Inc. | 7.87% | 4,932,825 | SCHEDULE 13G, 2026-03-18 | 2026-03-17 |
| Stonepine Capital Management, LLC | 7.2% | 625,000 | SCHEDULE 13G, 2026-08-31 | 2026-08-10 |
| Empery Asset Management, LP | 5.6% | 468,750 | SCHEDULE 13G, 2026-10-15 | 2026-09-30 |
Holding shares or following this stake? See who's behind Femasys Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Femasys Inc. and the records around it.
Femasys Inc. elsewhere on the record
- Company profile and every filing Aug 2026
- Form D filing Aug 2026
- Leadership changes Apr 2026
- Form D filing Nov 2025
- Who owns it
Companies that share a holder
- PharmaCyte Biotech, Inc. also filed stake reports on 1 other company: Q/C TECHNOLOGIES, INC. (Nov 2025)
- Dauntless Investment Group, LLC also filed stake reports on 3 other companies: KAZIA THERAPEUTICS LTD (Oct 2026), Azitra, Inc. (Jun 2026), OKYO Pharma Ltd (Feb 2026)
- Nantahala Capital Partners Limited Partnership also filed stake reports on 6 other companies: AZITRA, INC. (Aug 2026), ABEONA THERAPEUTICS INC. (May 2026), KIORA PHARMACEUTICALS, INC. (May 2026)
Watch Femasys Inc.
Get an email when Femasys Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Femasys Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Femasys Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Femasys Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Nantahala Capital Partners Limited Partnership | 0 | 803,038 | 0 | 803,038 | SCHEDULE 13D, 2026-08-17 |
| Nantahala Capital Management, LLC | 0 | 803,038 | 0 | 803,038 | SCHEDULE 13D, 2026-08-17 |
| Wilmot B. Harkey | 0 | 803,038 | 0 | 803,038 | SCHEDULE 13D, 2026-08-17 |
| Daniel Mack | 0 | 803,038 | 0 | 803,038 | SCHEDULE 13D, 2026-08-17 |
| Rosalind Advisors, Inc. | 0 | 4,687,500 | 0 | 4,687,500 | SCHEDULE 13G, 2026-08-14 |
| Salamon Steven A J | 0 | 4,687,500 | 0 | 4,687,500 | SCHEDULE 13G, 2026-08-14 |
| Aharon Gil | 0 | 4,687,500 | 0 | 4,687,500 | SCHEDULE 13G, 2026-08-14 |
| Rosalind Master Fund L.P. | 0 | 4,687,500 | 0 | 4,687,500 | SCHEDULE 13G, 2026-08-14 |
| Stonepine Capital Management, LLC | 0 | 625,000 | 0 | 625,000 | SCHEDULE 13G, 2026-08-31 |
| Stonepine Capital, L.P. | 0 | 625,000 | 0 | 625,000 | SCHEDULE 13G, 2026-08-31 |
| Stonepine GP, LLC | 0 | 625,000 | 0 | 625,000 | SCHEDULE 13G, 2026-08-31 |
| Jon M. Plexico | 0 | 625,000 | 0 | 625,000 | SCHEDULE 13G, 2026-08-31 |
| Empery Asset Management, LP | 0 | 468,750 | 0 | 468,750 | SCHEDULE 13G, 2026-10-15 |
| Ryan M. Lane | 0 | 468,750 | 0 | 468,750 | SCHEDULE 13G, 2026-10-15 |
The latest filing identifies Femasys Inc. by CUSIP 31447E204 and gives its principal executive office as 3950 Johns Creek Court, Suite 100, Suwanee, GA 30024 (SCHEDULE 13G, 2026-10-15).
Purpose of Transaction (Item 4)
Nantahala Capital Partners Limited Partnership
The disclosure regarding the SPA and the Purchase set forth above in Item 3 is incorporated herein by reference. The Issuer has further described the SPA, the Purchase and the Side Letter in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") on August 14, 2026. Pursuant to a side letter (the "Side Letter") entered into by Nantahala and the Issuer on August 7, 2026, for so long as Nantahala beneficially owns at least 15% of the outstanding shares of Common Stock (which determination shall be made without regard to the Beneficial Ownership Limitation), until the tenth anniversary of the Purchase, the board of directors (the "Board") of the Issuer shall appoint a Nantahala designee as a member of the Board (and any of its committees), subject to the reasonable agreement of the Issuer and applicable qualification requirements; Nantahala shall have the right to receive certain financial information and information presented to the Board, meet with Issuer management on a quarterly basis and be informed of certain material developments and events, subject to customary confidentiality obligations; and the Issuer shall refrain from taking certain actions without Nantahala's prior written consent, including entering into certain affiliated transactions, increasing the size of the Board, making certain terminations of, or replacing, the Issuer's chief executive officer, declaring certain dividends or distributions, incurring indebtedness in …The first part of Item 4 of the SCHEDULE 13D filed 2026-08-17; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-05 | Chernett Jorey | 9.3% | SCHEDULE 13G/A |
| 2025-09-04 | Alumni Capital LP | 9.99% | SCHEDULE 13G |
| 2025-11-14 | Dauntless Investment Group, LLC | 9.9% | SCHEDULE 13G/A |
| 2026-03-18 | PharmaCyte Biotech, Inc. | 7.87% | SCHEDULE 13G |
| 2026-08-14 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G |
| 2026-08-17 | Nantahala Capital Partners Limited Partnership | 9.99% | SCHEDULE 13D |
| 2026-08-31 | Stonepine Capital Management, LLC | 7.2% | SCHEDULE 13G |
| 2026-10-15 | Empery Asset Management, LP | 5.6% | SCHEDULE 13G |
Questions about who owns Femasys Inc.
Who owns Femasys Inc.?
On this page, 8 holders' latest ownership filings report 5% or more of Femasys Inc.: Alumni Capital LP (9.99%, Schedule 13G, filed 2025-09-04), Nantahala Capital Partners Limited Partnership (9.99%, Schedule 13D, filed 2026-08-17), Dauntless Investment Group, LLC (9.9%, Schedule 13G/A, filed 2025-11-14), Rosalind Advisors, Inc. (9.9%, Schedule 13G, filed 2026-08-14) and Chernett Jorey (9.3%, Schedule 13G/A, filed 2025-08-05); 3 more are listed above.
Who are the largest shareholders of Femasys Inc.?
By the share each holder's latest filing reports, the largest holders of Femasys Inc. on this page are Alumni Capital LP (9.99%), Nantahala Capital Partners Limited Partnership (9.99%) and Dauntless Investment Group, LLC (9.9%).
When did Alumni Capital LP buy into Femasys Inc.?
The filings give report dates, not purchase dates. The earliest filing from Alumni Capital LP on this page is the Schedule 13G, filed 2025-09-04, reporting 9.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Femasys Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 2, 2026 | Leadership change: Kenneth D. Eichenbaum departs, Director, and 2 more | — | Leadership changes | Source |
| August 20, 2026 | Form D, private offering | $30M sold | Form D page | Source |
| April 1, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| November 14, 2025 | Form D, private offering | $8.03M sold | Form D page | Source |
| June 10, 2025 | Form D, private offering | $1.45M sold | Form D page | Source |
| April 7, 2015 | Court case: Femasys, Inc. v. Norgenix Pharmaceuticals, LLC, District Court, N.D. Georgia | — | Court records | Source |
Femasys Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Femasys Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.